Prevalence of Chemotherapy-Induced Peripheral Neuropathy Among Cancer Patients and Its Effects on Quality of Life: A Survey Study Prevalence of CIPN and Its Impact on QoL
Article Sidebar
Main Article Content
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of cancer treatment, leading to nerve damage and impairing patients' quality of life.
Objective: To evaluate the prevalence of CIPN among cancer patients and its effects on their quality of life.
Methods: A cross-sectional study was conducted at Allied Hospital, Pinum Cancer Hospital, and Aziz Fatima Hospital in Faisalabad, Pakistan. The study included 54 cancer patients (20 males, 34 females) aged 13-71 years, undergoing chemotherapy for at least six months. Patients were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy Induced Peripheral Neuropathy 20-item scale (EORTC-QLQ-CIPN20) and the Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS). Data were analyzed using SPSS version 25, with descriptive statistics and chi-square tests performed to evaluate associations.
Results: CIPN was prevalent in 90.7% of patients, with mild (59.3%), moderate (27.8%), and severe (3.7%) neuropathy levels. Neuropathy was significantly correlated with reduced quality of life (p = 0.663).
Conclusion: CIPN is highly prevalent among cancer patients and significantly affects their quality of life. Early detection and management are crucial to mitigate these effects.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Weinberg RA, Weinberg RA. The Biology of Cancer. New York: WW Norton & Company; 2006.
Boutry J, Tissot S, Ujvari B, Capp JP, Giraudeau M, Nedelcu AM, et al. The Evolution and Ecology of Benign Tumors. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2022;1877(1):188643.
Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discovery. 2022;12(1):31-46.
Khani Y, Pourgholam-Amiji N, Afshar M, Otroshi O, Sharifi-Esfahani M, Sadeghi-Gandomani H, et al. Tobacco Smoking and Cancer Types: A Review. Biomedical Research and Therapy. 2018;5(4):2142-59.
Hassan M, Ansari J, Spooner D, Hussain S. Chemotherapy for Breast Cancer. Oncology Reports. 2010;24(5):1121-31.
Hurwitz M. Chemotherapy in Prostate Cancer. Current Oncology Reports. 2015;17(10):44.
Franceschi S, Bidoli E. The Epidemiology of Lung Cancer. Annals of Oncology. 1999;10.
Carling T, Udelsman R. Thyroid Cancer. Annual Review of Medicine. 2014;65(1):125-37.
Egas-Bejar D, Huh WW. Rhabdomyosarcoma in Adolescent and Young Adult Patients: Current Perspectives. Adolescent Health, Medicine and Therapeutics. 2014;5:115-25.
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. International Journal of Molecular Sciences. 2019;20(6):1451.
Almeida FC, Castilho A, Cesarino CB, Ribeiro RdCHM, Martins MRI. Correlation Between Neuropathic Pain and Quality of Life. Brazilian Journal of Pain. 2018;1(4):349-53.
Bao T, Baser R, Chen C, Weitzman M, Zhang YL, Seluzicki C, et al. Health-Related Quality of Life in Cancer Survivors With Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial. The Oncologist. 2021;26(11).
Simon NB, Danso MA, Alberico T, Basch EM, Bennett AV. The Prevalence and Pattern of Chemotherapy-Induced Peripheral Neuropathy Among Women With Breast Cancer Receiving Care in a Large Community Oncology Practice. J Clin Oncol. 2015;33(15_suppl).
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, Prevalence, and Predictors of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Pain. 2014;155(12):2461-70.
Mielke S, Sparreboom A, Mross K. Peripheral Neuropathy: A Persisting Challenge in Paclitaxel-Based Regimens. European Journal of Cancer. 2006;42(1):24-30.
Cavaletti G, Marmiroli P. Chemotherapy-Induced Peripheral Neurotoxicity. Nature Reviews Neurology. 2010;6(12):657-66.
Sisa C, Williams SA, He H, Liu Z, Partridge AH. Association of Chemotherapy-Induced Peripheral Neuropathy With Patient-Reported Symptoms, Physical Activity, and Health-Related Quality of Life in Breast Cancer Survivors. Journal of Clinical Oncology. 2020;38(29_suppl):69.
Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. Oxaliplatin-Induced Peripheral Neuropathy's Effects on Health-Related Quality of Life in Colorectal Cancer Survivors. Supportive Care in Cancer. 2013;21(12):3307-13.
Dougherty PM, Cata JP, Cordella JV, Burton AW, Weng HR. Taxol-Induced Sensory Disturbance. Cancer Chemotherapy and Pharmacology. 2004;53(5):366-72.
Ma J, Kavelaars A, Dougherty PM, Heijnen CJ. Beyond Symptomatic Relief: Strategies to Prevent and Improve Chemotherapy-Induced Peripheral Neuropathy. Current Opinion in Supportive and Palliative Care. 2018;12(2):123-31.